Onduo takes its time
The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.
Medtechs rake in the venture cash
In terms of private investments, 2020 was the year of the liquid biopsy.
How low can medtech venture investment go?
2019’s medtech VC total is swollen by the sector’s first $1bn round, but counterintuitively the amount going to smaller groups is increasing.
Medtech VC and the billion-dollar era
The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
Corporate VC activity in medtech increases – until this year
In 2018 more than a quarter of medtech funding came from rounds in which corporate VCs took part.
Auris acquisition could prompt more mega VC rounds
The J&J-Auris tie-up will yield a huge return for investors who went in big.
J&J’s Auris buy looks like a Verb swerve
Johnson & Johnson’s $3.4bn move for the robotic surgery specialist Auris Health could be bad news for its Verb Surgical joint venture.